Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Gets CE Mark for COVID-19, Flu A/B, RSV Kit

NEW YORK – Thermo Fisher Scientific said on Monday that it has received CE-marking for its TaqPath COVID-19, Flu A/B, RSV Combo Kit for the diagnosis of SARS-CoV-2, influenza A/B, and respiratory syncytial virus A/B infections.

The PCR-based kit allows laboratories to test for the diseases, which share clinical symptoms, in approximately three hours. Test results are analyzed using the Applied Biosystems Pathogens Interpretive Software, which automatically converts genetic analysis data into a report, reducing the risk of user interpretation error.

The new kit complements Thermo Fisher's previously launched TaqPath COVID-19 Combo Kit and RT-PCR CE-IVD.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.